Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed

British Journal of Ophthalmology

Volumn 97, Issue 8, 2013, Pages 1040-1044

  Joshi, Lavnish ^a,b   Yaganti, Satish ^a   Gemenetzi, Maria ^a   Lightman, Sue ^a,b   Lindfield, Dan ^a   Liolios, Vasilis ^a   Menezo, Victor ^a,c   Shao, Emily ^a   Taylor, Simon R J ^a,d  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Institut Catala de Retina   (Spain)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DEXAMETHASONE;

ADULT; AGED; ARTICLE; AS NEEDED REPEAT INJECTION PROTOCOL; BRANCHED RETINA VEIN OCCLUSION; CASE STUDY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; FEMALE; HUMAN; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MALE; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RELAPSE; REPEATED DRUG DOSE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

RETINA; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84880041946     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303207     Document Type: Article

References (23)

1. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1113-23. e15.
2. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117: 1094-101.e5.
3. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-82.
4. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-33.
5. Shirodkhar AL, Lightman S, Taylor SR. Management of branch retinal vein occlusion. Br J Hosp Med (Lond) 2012;73:20-3.
6. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46. e3
7. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60.
8. Moisseiev E, Goldstein M, Waisbourd M, et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 2013;27:65-71.
9. Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (ozurdex(R)) for retinal vein occlusion. Ophthalmologica 2013;229:21-5.
10. Gallego-Pinazo R, Dolz-Marco R, Pardo-Lopez D, et al. Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 2013;251:9-14.
11. Yunoki T, Miyakoshi A, Nakamura T, et al. Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol 2012;56:159-64.
12. Coscas G, Coscas F, Zucchiatti I, et al. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex(R). Eur J Ophthalmol 2011;21:631-6.
13. National Institute for Health and Clinical Excellence. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. Secondary Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion 2011. http://guidance. nice.org.uk/nicemedia/live/13037/54692/54692.pdf (accessed 5 Feb 2013).
14. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50.
15. Wong IY, Iu LP, Koizumi H, et al. The inner segment/outer segment junction: what have we learnt so far? Curr Opin Ophthalmol 2012;23:210-18.
16. Domalpally A, Peng Q, Danis R, et al. Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13. Eye (Lond) 2012;26:919-24.
17. Joshi L, Tomkins-Netzer O, Menezo V, et al. Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion. Acta Ophthalmol 2012;91:e239-40.
18. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol 2011;5:1043-9.
19. Ip MS, Scott IU, VanVeldhuisen PC, et al . A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
20. Scott IU, Ip MS, VanVeldhuisen PC, et al . A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
21. Chan CK, Ip MS, Vanveldhuisen PC, et al. SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 2011;118:1364-72.
22. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116:921-6.
23. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-7. (Pubitemid 39602140)